This study is creating a registry to better understand a treatment called Irreversible Electroporation (IRE) for pancreatic cancer. IRE is a procedure that uses electrical pulses to destroy cancer cells. The registry will collect information from 500 adult patients with pancreatic cancer who are eligible for this type of soft tissue ablation. The goal is to learn more about how doctors choose to use IRE, how well it works, and any side effects or complications. This information will help doctors provide the best care for patients needing surgical interventions for pancreatic cancer. You can join if you are an adult (18 or older) with pancreatic cancer and your doctor thinks you are a good candidate for soft tissue ablation. You cannot join if you have a pacemaker, certain metal implants near the tumor, or have had a heart attack recently.

Study design

This is an observational study, meaning researchers will collect information about patients who receive IRE treatment. It aims to include 500 participants.

What's involved

Not specified in the trial record.

Compensation

Not stated in the trial record.

Follow-up

Adverse events will be measured for up to 5 years after treatment.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.